Beleaguered Actelion faces $547M court judgment

Just as Actelion's executive team was gearing up for a showdown on Thursday with a rebellious crew of insurgent shareholders, the company was hit with a $547 million court judgment. Report

Suggested Articles

Six pharmaceutical execs are set to head to Washington next week for pricing hearings at the House Committee on Oversight and Reform. 

After sifting through the data, one analyst figures the latest Opdivo-Keytruda showdown in kidney cancer might come down to commercial execution.

Biogen is giving former chief finance officer Jeff Capello a multimillion-dollar cash payment plus other severance benefits.